Untitled source document
No live link available for this source.
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis in the United States
80% confidenceFor chronic spontaneous urticaria, 6.5 million people are estimated to be diagnosed and treated with antihistamines or biologics today in China
80% confidenceThe approval of neffy in China represents a significant advancement for the millions of patients and caregivers managing severe allergic reactions whose only option until now was to seek emergency medical help without the option to self-administer epinephrine in a community setting
80% confidenceARS Pharma and Pediatrix Therapeutics anticipate filing for approval of neffy 1 mg dose for children greater than 15 kg and less than 30 kg in the coming months
80% confidenceThis innovation can meaningfully improve preparedness, confidence, and outcomes for patients and families across China
80% confidenceApproximately 4.0% to 8.2% of the population of China (about 50 to 100 million people) is estimated to be affected by food allergies and at risk for severe allergic reactions
80% confidenceOf those who filled prescriptions, only half consistently carry their prescribed auto-injector
80% confidenceMore than half of patients or caregivers who carry an auto-injector either delay or do not administer the device when needed in an emergency
80% confidenceApproval in New Zealand is expected by the end of 2025
80% confidenceThere are approximately 40 million people in the United States who experience Type I allergic reactions
80% confidenceIn 2023, only 3.2 million filled their active epinephrine auto-injector prescription in the United States
80% confidenceAs the first community use epinephrine product available in the Chinese market, neffy has the potential to transform how severe allergies are treated, enabling earlier epinephrine use at the first signs of symptoms and reducing barriers that can delay care
80% confidence